These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23773289)

  • 1. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model.
    Ma L; Nagai J; Chun J; Ueda H
    Mol Pain; 2013 Jun; 9():29. PubMed ID: 23773289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
    Uchida H; Nagai J; Ueda H
    Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
    J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1β plays key roles in LPA-induced amplification of LPA production in neuropathic pain model.
    Yano R; Ma L; Nagai J; Ueda H
    Cell Mol Neurobiol; 2013 Nov; 33(8):1033-41. PubMed ID: 23949386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
    Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia.
    Ueda H
    Pain Manag; 2020 Jan; 10(1):43-53. PubMed ID: 31852400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems Pathology of Neuropathic Pain and Fibromyalgia.
    Ueda H
    Biol Pharm Bull; 2019; 42(11):1773-1782. PubMed ID: 31685762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain.
    Ma L; Nagai J; Ueda H
    J Neurochem; 2010 Nov; 115(3):643-53. PubMed ID: 20722972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain.
    Inoue M; Ma L; Aoki J; Ueda H
    J Neurochem; 2008 Dec; 107(6):1556-65. PubMed ID: 19014389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
    Velasco M; O'Sullivan C; Sheridan GK
    Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of lysophosphatidic acid-induced astrocyte activation underlying the maintenance of partial sciatic nerve injury-induced neuropathic pain.
    Ueda H; Neyama H; Nagai J; Matsushita Y; Tsukahara T; Tsukahara R
    Pain; 2018 Nov; 159(11):2170-2178. PubMed ID: 29939962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain.
    Lin ME; Rivera RR; Chun J
    J Biol Chem; 2012 May; 287(21):17608-17617. PubMed ID: 22461625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid receptor
    Hoshino Y; Okuno T; Saigusa D; Kano K; Yamamoto S; Shindou H; Aoki J; Uchida K; Yokomizo T; Ito N
    FASEB J; 2022 Apr; 36(4):e22236. PubMed ID: 35218596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
    Ueda H; Neyama H; Matsushita Y
    Cells; 2020 Aug; 9(8):. PubMed ID: 32824296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidic acid and its receptor LPA
    Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
    Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two pathways for lysophosphatidic acid production.
    Aoki J; Inoue A; Okudaira S
    Biochim Biophys Acta; 2008 Sep; 1781(9):513-8. PubMed ID: 18621144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic acid as the initiator of neuropathic pain.
    Ueda H
    Biol Pharm Bull; 2011; 34(8):1154-8. PubMed ID: 21804198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid: chemical signature of neuropathic pain.
    Ueda H; Matsunaga H; Olaposi OI; Nagai J
    Biochim Biophys Acta; 2013 Jan; 1831(1):61-73. PubMed ID: 22960381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPA
    Wang F; Liu S; Pei J; Cai L; Liu N; Liang T; Dong X; Cong X; Chun J; Chen J; Hu S; Chen X
    Theranostics; 2020; 10(24):10892-10907. PubMed ID: 33042260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.